Akhil Saji, MD, and Amir Lebastchi, MD, discuss the advancements and applications of focal therapy for prostate cancer, exploring the evolution of this treatment, current standards, ideal patient selection, and the use of cutting-edge technologies like HIFU and IRE. The conversation also highlights the integration of MRI, biomarkers, and tailored follow-up strategies, as well as approaches for addressing recurrences.
Focal Therapy in Prostate Cancer Treatment: An Overview
By Akhil Abraham Saji, MD, Amir H. Lebastchi, MD - Last Updated: January 2, 2025Related Posts
Dr. Sonpavde showcases a phase I/Ib clincial trial on the safety of a neoadjuvant darolutamide and relugolix combination.
Dr. Keizman showcases his research on using Decipher for early prostate cancer for USA versus non-USA populations.
Dr. Ghoreifi characterizes the activity of inflammasome genes and their association with oncological outcomes in PC.
Patients with very high-risk disease saw greater benefit from long-term ADT use compared to those with high-risk disease.
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.